Dipanjan Panda, Disha Tiwari, Atul Sharma, D. Kishan
{"title":"伊鲁替尼诱导感觉运动神经病变:一种新的副作用","authors":"Dipanjan Panda, Disha Tiwari, Atul Sharma, D. Kishan","doi":"10.18231/j.ijpo.2023.035","DOIUrl":null,"url":null,"abstract":"Chemotherapy-induced peripheral neuropathy (CIPN) is a well-documented toxicity leading to dose limitation.Ibrutinib is an oral Bruton’s Tyrosine Kinase (BTK) inhibitor approved for treating chronic lymphocytic lymphoma. The most common neurological side effects of Ibrutinib include headache and dizziness. Herein, we report peripheral neuropathy as a dose-limiting manifestation of Ibrutinib treatment.","PeriodicalId":446035,"journal":{"name":"Indian Journal of Pathology and Oncology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ibrutinib induced sensorimotor neuropathy: A novel side effect\",\"authors\":\"Dipanjan Panda, Disha Tiwari, Atul Sharma, D. Kishan\",\"doi\":\"10.18231/j.ijpo.2023.035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chemotherapy-induced peripheral neuropathy (CIPN) is a well-documented toxicity leading to dose limitation.Ibrutinib is an oral Bruton’s Tyrosine Kinase (BTK) inhibitor approved for treating chronic lymphocytic lymphoma. The most common neurological side effects of Ibrutinib include headache and dizziness. Herein, we report peripheral neuropathy as a dose-limiting manifestation of Ibrutinib treatment.\",\"PeriodicalId\":446035,\"journal\":{\"name\":\"Indian Journal of Pathology and Oncology\",\"volume\":\"37 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Pathology and Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.ijpo.2023.035\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pathology and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijpo.2023.035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ibrutinib induced sensorimotor neuropathy: A novel side effect
Chemotherapy-induced peripheral neuropathy (CIPN) is a well-documented toxicity leading to dose limitation.Ibrutinib is an oral Bruton’s Tyrosine Kinase (BTK) inhibitor approved for treating chronic lymphocytic lymphoma. The most common neurological side effects of Ibrutinib include headache and dizziness. Herein, we report peripheral neuropathy as a dose-limiting manifestation of Ibrutinib treatment.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
